{"slug":"adc","tag":"adc","variants":["adc"],"description":"No description yet","count":12,"kinds":{"person":12},"related":[{"slug":"breast","tag":"breast","shared":4},{"slug":"trialist","tag":"trialist","shared":3},{"slug":"her2","tag":"her2","shared":2},{"slug":"lymphoma","tag":"lymphoma","shared":2},{"slug":"ovarian","tag":"ovarian","shared":2},{"slug":"urothelial","tag":"urothelial","shared":2},{"slug":"canada","tag":"canada","shared":1},{"slug":"cervical","tag":"cervical","shared":1},{"slug":"cooperative-group","tag":"cooperative-group","shared":1},{"slug":"ctdna","tag":"ctdna","shared":1},{"slug":"her2-low","tag":"her2-low","shared":1},{"slug":"hodgkin","tag":"hodgkin","shared":1}],"records":[{"id":"ian-krop","kind":"person","name":"Ian E. Krop","route":"/people/ian-krop/","tldr":"Breast oncologist who took T-DM1 and then trastuzumab deruxtecan from first-in-human studies to approval."},{"id":"shanu-modi","kind":"person","name":"Shanu Modi","route":"/people/shanu-modi/","tldr":"Led DESTINY-Breast01 and DESTINY-Breast04, the trials that created the HER2-low category and opened T-DXd to most breast cancers."},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/","tldr":"Spanish breast oncologist leading DESTINY-Breast09, which moved trastuzumab deruxtecan into first-line HER2-positive disease."},{"id":"aditya-bardia","kind":"person","name":"Aditya Bardia","route":"/people/aditya-bardia/","tldr":"Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant."},{"id":"thomas-powles","kind":"person","name":"Thomas Powles","route":"/people/thomas-powles/","tldr":"Led EV-302, NIAGARA and IMvigor011, the trials that transformed bladder cancer from chemotherapy-only to ADC, immunotherapy and ctDNA-guided care."},{"id":"jonathan-rosenberg","kind":"person","name":"Jonathan E. Rosenberg","route":"/people/jonathan-rosenberg/","tldr":"Led the early enfortumab vedotin trials and the atezolizumab study that first brought immunotherapy to bladder cancer."},{"id":"kathleen-moore","kind":"person","name":"Kathleen N. Moore","route":"/people/kathleen-moore/","tldr":"Led SOLO-1 and MIRASOL, which gave ovarian cancer a maintenance PARP inhibitor and its first ADC with a survival benefit."},{"id":"ignace-vergote","kind":"person","name":"Ignace Vergote","route":"/people/ignace-vergote/","tldr":"Led the EORTC trial that made neoadjuvant chemotherapy acceptable in ovarian cancer and innovaTV 301, the first ADC survival win in cervical cancer."},{"id":"herve-tilly","kind":"person","name":"Hervé Tilly","route":"/people/herve-tilly/","tldr":"Principal investigator of POLARIX, the trial that gave DLBCL its first improvement on R-CHOP in twenty years."},{"id":"joseph-connors","kind":"person","name":"Joseph M. Connors","route":"/people/joseph-connors/","tldr":"Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma."},{"id":"steven-horwitz","kind":"person","name":"Steven M. Horwitz","route":"/people/steven-horwitz/","tldr":"Led ECHELON-2, the first trial to improve survival in peripheral T-cell lymphoma, using brentuximab vedotin."},{"id":"sagar-lonial","kind":"person","name":"Sagar Lonial","route":"/people/sagar-lonial/","tldr":"Led SIRIUS and the DREAMM programme, bringing daratumumab monotherapy and the BCMA ADC belantamab to myeloma."}]}